← FDA DRUG APPROVALS

FDA NDA · NDA018689

RIDAURA

auranofin

Sponsor: LEGACY

APPLICATION
NDA018689
TYPE
NDA
ORIGINAL APPROVAL
1985-05-24
LATEST ACTION
2013-05-14
ROUTE
ORAL
DOSAGE FORM
CAPSULE
MARKETING STATUS
Prescription

Products

RIDAURA · ReferencePrescription
AURANOFIN 3MG · CAPSULE · ORAL

Approval history

2013-05-14Manufacturing (CMC) · Supplement 18 · priorityAP
2002-05-23Manufacturing (CMC) · Supplement 16 · priorityAP
1999-12-22Manufacturing (CMC) · Supplement 14 · priorityAP
1999-12-22Labeling · Supplement 15 · standardAP
1998-04-23Labeling · Supplement 12AP
1998-04-23Labeling · Supplement 11AP
1996-01-02Manufacturing (CMC) · Supplement 13 · priorityAP
1989-04-13Labeling · Supplement 10AP
1987-11-02Labeling · Supplement 7AP
1987-11-02Labeling · Supplement 8AP
1987-04-27Labeling · Supplement 6AP
1985-05-24Type 1 - New Molecular Entity · Original · priorityReviewAP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industryGMP disciplineFDA drug shortagesFDA enforcement & recalls

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →